NARI - Inari Medical Inc Stock Price, Fair Value and News

41.85USD-0.96 (-2.24%)Delayed as of 08 May 2024, 03:05 pm ET

Market Summary

USD41.85-0.96

Delayedas of 08 May 2024, 03:05 pm

-2.24%

NARI Alerts

2 major insider sales recently.

Big fall in earnings (Y/Y)
Losses in recent quarter

NARI Stock Price

View Fullscreen

NARI RSI Chart

NARI Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-105.37

Price/Sales (Trailing)

4.78

EV/EBITDA

-2.4K

Price/Free Cashflow

120.49

NARI Price/Sales (Trailing)

NARI Profitability

EBT Margin

-2.04%

Return on Equity

-5.28%

Return on Assets

-3.57%

Free Cashflow Yield

0.83%

NARI Fundamentals

NARI Revenue

Revenue (TTM)

520.7M

Rev. Growth (Yr)

23.27%

Rev. Growth (Qtr)

8.4%

NARI Earnings

Earnings (TTM)

-23.6M

Earnings Growth (Yr)

-991.16%

Earnings Growth (Qtr)

-418.8%

Breaking Down NARI Revenue

52 Week Range

41.4871.85

(Low)(High)

Last 7 days

14.7%

Last 30 days

1.6%

Last 90 days

-24.4%

Trailing 12 Months

-34.9%

How does NARI drawdown profile look like?

NARI Financial Health

Current Ratio

2.71

NARI Investor Care

Shares Dilution (1Y)

1.69%

Diluted EPS (TTM)

-0.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	520.7M	0	0	0
2023	412.9M	439.1M	469.3M	493.6M
2022	306.3M	335.6M	358.9M	383.5M
2021	170.1M	208.2M	242.4M	277.0M
2020	71.1M	86.5M	110.9M	139.7M
2019	0	21.6M	36.4M	51.1M
2018	0	0	0	6.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Inari Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	hoffman william	sold	-1,619,050	41.9997	-38,549	-
Apr 24, 2024	chambers rebecca	acquired	174,984	42.41	4,126	-
Apr 24, 2024	lucchese cynthia l	acquired	174,984	42.41	4,126	-
Apr 24, 2024	szyman catherine m.	acquired	174,984	42.41	4,126	-
Apr 24, 2024	milder donald b	acquired	174,984	42.41	4,126	-
Apr 24, 2024	warner robert keith	acquired	174,984	42.41	4,126	-
Apr 24, 2024	hoffman william	acquired	174,984	42.41	4,126	-
Apr 24, 2024	root jonathan d	acquired	174,984	42.41	4,126	-
Apr 24, 2024	mead dana g jr.	acquired	174,984	42.41	4,126	-
Apr 16, 2024	hoffman william	sold	-58,040	40.00	-1,451	-

Which funds bought or sold NARI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Candriam S.C.A.	new	-	2,835,380	2,835,380	0.02%
May 06, 2024	Jefferies Financial Group Inc.	sold off	-100	-500,245	-	-%
May 06, 2024	SG Americas Securities, LLC	reduced	-48.03	-870,000	542,000	-%
May 06, 2024	TEXAS PERMANENT SCHOOL FUND CORP	added	1.5	-716,787	2,152,290	0.02%
May 06, 2024	Parallel Advisors, LLC	reduced	-0.05	-891,035	2,518,760	0.07%
May 06, 2024	HighTower Advisors, LLC	added	7.25	-823,000	3,159,000	-%
May 03, 2024	Larson Financial Group LLC	new	-	96.00	96.00	-%
May 03, 2024	BI Asset Management Fondsmaeglerselskab A/S	new	-	30,000	30,000	-%
May 03, 2024	ESSEX INVESTMENT MANAGEMENT CO LLC	sold off	-100	-3,945,510	-	-%
May 03, 2024	Householder Group Estate & Retirement Specialist, LLC	new	-	14,298	14,298	-%

Are Funds Buying or Selling NARI?

Are funds buying NARI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NARI

No. of Funds

Unveiling Inari Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 03, 2024	millennium management llc	3.8%	2,181,337	SC 13G
Feb 14, 2024	point72 asset management, l.p.	1.2%	668,429	SC 13G/A
Feb 13, 2024	vanguard group inc	8.75%	5,038,292	SC 13G/A
Feb 08, 2024	wellington management group llp	7.92%	4,563,325	SC 13G/A
Feb 08, 2024	milder donald b	5.4%	3,084,302	SC 13G/A
Jan 24, 2024	blackrock inc.	11.6%	6,696,598	SC 13G/A
Feb 24, 2023	point72 asset management, l.p.	4.9%	2,611,241	SC 13G
Feb 14, 2023	macquarie group ltd	3.38%	1,814,852	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	4.1%	2,183,673	SC 13G/A
Feb 13, 2023	capital international investors	0.1%	72,099	SC 13G/A

Recent SEC filings of Inari Medical Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	4	Insider Trading
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading

Peers (Alternatives to Inari Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.5B	40.3B	-4.60%	-4.35%	32.81	4.58	-2.84%	-3.08%
BDX	68.5B	19.7B	-3.65%	-5.69%	51.42	3.48	4.82%	-17.56%
ALGN	21.6B	3.9B	-9.77%	-6.38%	46.66	5.51	5.72%	46.72%
BAX	18.4B	14.9B	-15.25%	-20.81%	6.95	1.24	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	5.58%	23.16%	31.71	2.8	6.16%	35.06%
HSIC	9.1B	12.5B	-1.81%	-10.76%	23.5	0.73	-0.61%	-18.83%
BIO	8.2B	2.7B	-13.87%	-26.12%	-12.81	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-12.53%	-31.61%	-62.76	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.76	8.88	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.87	0.4	7.94%	-1661.78%
ANIK	420.5M	166.7M	10.85%	9.31%	-5.09	2.52	6.67%	-456.34%
ANGO	245.9M	324.0M	-12.80%	-31.58%	-1.28	0.76	-3.19%	-337.41%
APYX	48.8M	52.3M	-6.00%	-59.48%	-2.61	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-25.71%	271.43%	-0.27	0.89	5.77%	8.23%

Inari Medical Inc News

Latest updates

Inari Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	8.4%	143,194,000	132,094,000	126,366,000	119,005,000	116,167,000	107,771,000	96,204,000	92,744,000	86,752,000	83,218,000	72,916,000	63,453,000	57,397,000	48,610,500	38,715,000	25,392,000	26,953,000	19,887,000	14,225,000	10,072,000	-
Gross Profit	8.0%	124,301,000	115,088,000	111,889,000	105,161,000	102,426,000	94,643,000	85,140,000	82,397,000	76,785,000	74,938,000	65,876,000	58,639,000	52,774,000	44,925,000	35,487,000	21,905,000	24,247,000	17,748,000	12,715,000	8,741,000	-
Operating Expenses	13.7%	141,478,000	124,385,000	109,776,000	106,671,000	107,764,000	100,534,000	94,938,000	91,725,000	79,867,000	73,192,000	68,603,000	54,527,000	45,061,000	37,929,000	28,297,000	22,508,000	19,411,000	16,578,000	11,822,000	9,383,000	-
S&GA Expenses	1.5%	103,055,000	101,493,000	88,284,000	85,586,000	85,700,000	80,122,000	75,833,000	73,156,000	63,732,000	54,466,000	56,104,000	42,897,000	36,898,000	31,393,000	23,080,000	18,880,000	16,393,000	13,869,000	10,100,000	7,803,000	-
R&D Expenses	17.4%	26,880,000	22,892,000	21,492,000	21,085,000	22,064,000	20,412,000	19,105,000	18,569,000	16,135,000	18,726,000	12,499,000	11,630,000	8,163,000	6,536,000	5,217,000	3,628,000	3,018,000	2,709,000	1,722,000	1,580,000	-
EBITDA Margin	-108.4%	0.00	0.02	0.02	-0.02	-0.05	-0.06	-0.04	-0.03	0.01	0.05	0.08	0.13	-	-	-	-	-	-	-	-	-
Interest Expenses	13.0%	78,000	69,000	43,000	44,000	40,000	74,000	74,000	73,000	73,000	75,000	73,000	74,000	73,000	75,000	251,000	463,000	346,000	238,000	226,000	229,000	-
Income Taxes	444.3%	8,115,000	1,491,000	2,428,000	939,000	1,024,000	990,000	840,000	1,252,000	-	574,000	61,000	12,000	198,000	-	-	-	-	-11,000	1,000	-	-
Earnings Before Taxes	-406.8%	-16,087,000	-3,174,000	5,590,000	3,024,000	-1,194,000	-4,808,000	-9,313,000	-8,935,000	-3,129,000	1,681,000	-2,743,000	4,080,000	7,667,000	6,985,000	6,496,000	-3,804,000	4,112,000	-	-	-	-
EBT Margin	-337.7%	-0.02	0.01	0.01	-0.03	-0.06	-0.07	-0.05	-0.04	0.00	0.04	0.07	0.12	-	-	-	-	-	-	-	-	-
Net Income	-418.8%	-24,202,000	-4,665,000	3,162,000	2,085,000	-2,218,000	-5,798,000	-10,153,000	-10,187,000	-3,129,000	1,107,000	-2,804,000	4,068,000	7,469,000	6,985,000	6,496,000	-3,804,000	4,112,000	355,000	366,000	-965,000	-
Net Income Margin	-1268.9%	-0.05	0.00	-0.01	-0.04	-0.07	-0.08	-0.06	-0.04	0.00	0.04	0.06	0.12	-	-	-	-	-	-	-	-	-
Free Cashflow	-219.5%	-13,538,000	11,332,000	14,331,000	8,531,000	-2,977,000	9,477,000	-15,375,000	-6,180,000	-11,845,000	12,289,000	-10,330,000	2,381,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-1.8%	662	674	549	525	507	504	488	484	484	312	292	254	235	214	206	224	45.00
Current Assets	-1.0%	233	236	469	445	426	423	411	411	413	245	228	228	221	206	199	220	39.00
Cash Equivalents	72.8%	67.00	39.00	89.00	58.00	57.00	60.00	84.00	80.00	187	93.00	81.00	91.00	103	115	24.00	195	24.00
Inventory	4.1%	45.00	43.00	40.00	39.00	36.00	33.00	30.00	27.00	24.00	21.00	19.00	18.00	14.00	11.00	7.00	6.00	4.00
Net PPE	-0.8%	21.00	21.00	21.00	21.00	21.00	22.00	21.00	20.00	18.00	16.00	15.00	11.00	7.00	7.00	5.00	4.00	3.00
Goodwill	-2.2%	210	214	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	2.5%	215	209	97.00	89.00	80.00	87.00	73.00	70.00	65.00	72.00	58.00	32.00	21.00	14.00	14.00	40.00	30.00
Current Liabilities	12.7%	86.00	76.00	66.00	58.00	48.00	56.00	42.00	41.00	36.00	43.00	30.00	32.00	21.00	14.00	14.00	11.00	9.00
Shareholder's Equity	-3.8%	447	465	452	436	427	417	415	414	419	239	234	222	214	200	191	184	-
Retained Earnings	-49.9%	-72.69	-48.49	-43.82	-46.98	-49.07	-46.85	-41.05	-30.90	-20.71	-17.58	-18.69	-15.89	-19.95	-27.42	-34.41	-40.90	-41.21
Additional Paid-In Capital	2.8%	518	504	497	484	476	463	457	446	440	257	253	238	234	228	226	225	2.00
Shares Outstanding	0.4%	58.00	58.00	58.00	57.00	55.00	54.00	53.00	53.00	51.00	50.00	50.00	50.00	-	-	-	-	-
Float	-	-	-	-	2,830	-	-	-	3,280	-	-	-	3,950	-	-	-	954	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-200.4%	-12,288	12,241	15,939	9,760	-2,013	11,255	-13,066	-3,061	-9,100	15,007	-5,589	7,302	8,766	-1,624	5,341	-1,126	-679	-826	-335	-	-
Share Based Compensation	31.3%	12,870	9,801	9,844	10,353	10,339	7,596	7,356	7,164	6,555	4,509	12,499	4,604	3,836	1,565	959	506	494	176	139	-	-
Cashflow From Investing	165.6%	39,162	-59,716	11,821	-6,080	-4,043	-33,247	13,402	-101,860	-73,511	-2,657	-7,428	-18,426	-22,511	-52,361	-1,658	-809	-609	-1,082	-1,163	-	-
Cashflow From Financing	142.1%	1,015	-2,410	3,467	-2,352	2,466	-1,689	3,880	-1,595	176,542	-620	2,993	-514	2,214	226	-30,531	164,398	10,022	10,025	178	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NARI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 143,194,000	$ 116,167,000
Cost of goods sold	18,893,000	13,741,000
Gross profit	124,301,000	102,426,000
Operating expenses
Research and development	26,880,000	22,064,000
Selling, general and administrative	103,055,000	85,700,000
Change in fair value of contingent consideration	6,303,000	0
Amortization of intangible asset	2,461,000	0
Acquisition-related expenses	2,779,000	0
Total operating expenses	141,478,000	107,764,000
Loss from operations	(17,177,000)	(5,338,000)
Other income (expense)
Interest income	1,191,000	4,145,000
Interest expense	(78,000)	(40,000)
Other (expense) income	(23,000)	39,000
Total other income	1,090,000	4,144,000
Loss before income taxes	(16,087,000)	(1,194,000)
Provision for income taxes	8,115,000	1,024,000
Net loss	(24,202,000)	(2,218,000)
Other comprehensive income (loss)
Foreign currency translation adjustments	(7,359,000)	9,000
Unrealized loss on available-for-sale debt securities	(4,000)	(865,000)
Total other comprehensive loss	(7,363,000)	(856,000)
Comprehensive loss	$ (31,565,000)	$ (3,074,000)
Net loss per share
Basic (in dollars per share)	$ (0.42)	$ (0.04)
Diluted (in dollars per share)	$ (0.42)	$ (0.04)
Weighted average common shares used to compute net loss per share
Basic (in shares)	57,938,115	54,756,024
Diluted (in shares)	57,938,115	54,756,024

NARI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 66,707,000	$ 38,597,000
Restricted cash	500,000	611,000
Short-term investments in debt securities	34,595,000	76,855,000
Accounts receivable, net	78,621,000	70,119,000
Inventories, net	44,650,000	42,900,000
Prepaid expenses and other current assets	8,240,000	6,481,000
Total current assets	233,313,000	235,563,000
Property and equipment, net	20,761,000	20,929,000
Operating lease right-of-use assets	47,610,000	48,407,000
Goodwill	209,642,000	214,335,000
Intangible assets	145,774,000	150,884,000
Deposits and other assets	4,676,000	4,117,000
Total assets	661,776,000	674,235,000
Current liabilities
Accounts payable	12,026,000	10,577,000
Payroll-related accruals	38,748,000	48,706,000
Accrued expenses and other current liabilities	33,544,000	15,364,000
Operating lease liabilities, current portion	1,719,000	1,692,000
Total current liabilities	86,037,000	76,339,000
Operating lease liabilities, noncurrent portion	29,773,000	30,355,000
Deferred tax liability	35,395,000	36,231,000
Other long-term liability	63,341,000	66,400,000
Total liabilities	214,546,000	209,325,000
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 58,001,145 and 57,762,414 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	58,000	58,000
Additional paid in capital	518,338,000	504,453,000
Accumulated other comprehensive income	1,522,000	8,885,000
Accumulated deficit	(72,688,000)	(48,486,000)
Total stockholders' equity	447,230,000	464,910,000
Total liabilities and stockholders' equity	$ 661,776,000	$ 674,235,000

About Inari Medical Inc

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. The company provides ClotTriever, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

CEO	Mr. Andrew J. Hykes
WEBSITE	inarimedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1100

Inari Medical Inc Frequently Asked Questions

What is the ticker symbol for Inari Medical Inc? What does NARI stand for in stocks?

NARI is the stock ticker symbol of Inari Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inari Medical Inc (NARI)?

As of Tue May 07 2024, market cap of Inari Medical Inc is 2.49 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NARI stock?

You can check NARI's fair value in chart for subscribers.

What is the fair value of NARI stock?

You can check NARI's fair value in chart for subscribers. The fair value of Inari Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inari Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NARI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inari Medical Inc a good stock to buy?

The fair value guage provides a quick view whether NARI is over valued or under valued. Whether Inari Medical Inc is cheap or expensive depends on the assumptions which impact Inari Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NARI.

What is Inari Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, NARI's PE ratio (Price to Earnings) is -105.37 and Price to Sales (PS) ratio is 4.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NARI PE ratio will change depending on the future growth rate expectations of investors.